Week 232 Dopamine (And Movement/Parkinsons Disease)
To link the neurobiology of dopamine to its roles in both health and disease states
- 1.The dopamine-producing region of the brain which dies in Parkinsons disease is called the
- A.
Amygdala
- B.
Basal nucleus of Meynert
- C.
Locus Coeruleus
- D.
Raphe Nucleus
- E.
Substantia Nigra
- F.
Medical malpractice
- G.
Depersonalization
- H.
The Hippocratic oath
- I.
Reverse psychology
- J.
A vicious circle
- 2.Dopamine regulates movement principally through projections from the substantia nigra to the
- A.
Dorsal Striatum
- B.
Globus Pallidus
- C.
Motor Cortex
- D.
Subthalamic Nucleus
- E.
Ventral Striatum
- 3.The striatum, globus pallidus, substantia nigra and subthalamic nucleus are all part of the
- A.
Basal Ganglia
- B.
Brainstem
- C.
Cranial nerves
- D.
Hypothalamus
- E.
Thalamus
- 4.The substantia nigra is so named, and clearly visible on brain sections, because it
- A.
Is black
- B.
Is located outside of the four major lobes and looks like a 'little brain'
- C.
Is shaped like a seahorse
- D.
Is the major white matter structure linking the two hemispheres
- E.
Is very highly folded
- 5.Dopamine is broken down by
- A.
Acetylcholinesterase
- B.
Cyclooxygenase
- C.
Dopa decarboxylase
- D.
Dopaminase
- E.
Monoamine oxidase
- 6.L-DOPA is converted into dopamine by
- A.
Acetylcholinesterase
- B.
Cyclooxygenase
- C.
Dopa decarboxylase
- D.
Dopaminase
- E.
Monoamine oxidase
- 7.Patients with Parkinsons disease suffer from a lack of dopamine
- A.
True
- B.
False
- 8.Carbidopa is a
- A.
Dopa decarboxylase inhibitor
- B.
Dopamine receptor agonist
- C.
Dopamine reuptake inhibitor
- D.
Monoamine oxidase inhibitor
- E.
Stimulator of dopamine release
- 9.A dopa decaroxylase inhibitor (such as Carbidopa), which inhibits the conversion of L-DOPA into dopamine, should not be given to patients with Parkinsons disease
- A.
True
- B.
False
- 10.Selegiline is a
- A.
Dopa decarboxylase inhibitor
- B.
Dopamine receptor agonist
- C.
Dopamine reuptake inhibitor
- D.
Monoamine oxidase inhibitor
- E.
Stimulator of dopamine release
- 11.Entacapone is a
- A.
Dopa decarboxylase agonist
- B.
Catechol-O-methyl transferase inhibitor
- C.
Dopamine receptor antagonist
- D.
Monoamine oxidase agonist
- E.
Stimulator of dopamine breakdown
- F.
Cruelty
- G.
Assiduity
- H.
Determination
- I.
Delusions of grandeur
- J.
Work ethic
- 12.Ropinirole is a
- A.
Dopa decarboxylase inhibitor
- B.
Dopamine receptor agonist
- C.
Dopamine reuptake inhibitor
- D.
Monoamine oxidase inhibitor
- E.
Stimulator of dopamine release
- 13.Pramipexole is a
- A.
Dopa decarboxylase inhibitor
- B.
Dopamine receptor agonist
- C.
Dopamine reuptake inhibitor
- D.
Monoamine oxidase inhibitor
- E.
Stimulator of dopamine release
- 14.Possible side effects of dopamine agonists such as ropinirole and prampipexole include (tick all that apply)
- A.
Constipation
- B.
Hallucinations
- C.
Hypersexuality
- D.
Nausea
- E.
Pathological gambling
- 15.Metoclopramide is primarily used as an
- A.
Anticoagulant
- B.
Antidepressant
- C.
Antiemetic
- D.
Antihistamine
- E.
Antipsychotic
- 16.Haloperidol is primarily used as an
- A.
Anticoagulant
- B.
Antidepressant
- C.
Antiemetic
- D.
Antihistamine
- E.
Antipsychotic
- F.
A spiritual awakening
- G.
Crippling remorse
- H.
Mixed emotions
- I.
False dilemm
- J.
Homesickness
- 17.The use of haloperidol and metoclopramide in Parkinsons disease is potentially problematic because they
- A.
Block dopamine receptors
- B.
Block dopamine reuptake
- C.
Block dopamine synthesis
- D.
Stimulate dopamine receptors
- E.
Stimulate dopamine breakdown
- 18.The clinical potency of 'typical' antipsychotics shows good correlation with their ability to
- A.
Block dopamine release
- B.
Block dopamine D1 receptors
- C.
Block dopamine D2 receptors
- D.
Stimulate dopamine breakdown
- E.
Stimulate dopamine reuptake
- 19.Dyskinesia is best described as
- A.
Awareness of position and movement
- B.
Excessive, abnormal, random fidgety movements
- C.
Rhythmic oscillatory movement
- D.
Slow or sustained abnormal movement of limb
- E.
Stereotyped brief movement
- 20.Dopamine hydrochloride administered via the intravenous route does not cross the blood-brain barrier
- A.
True
- B.
False
Questions: 10 | Attempts: 1551 | Last updated: Dec 15, 2020
-
Sample QuestionWhat was Parkinson's Disease originally refered to?
Questions: 9 | Attempts: 12494 | Last updated: Sep 3, 2020
-
Sample QuestionHIV and AIDS are the same things.
Questions: 8 | Attempts: 11607 | Last updated: Sep 30, 2020
-
Sample QuestionWhere would you most like to live?
Back to top